Top

Published in:

01-06-2012 | Original Article

The effects of adiponectin and leptin on changes in bone mineral density

Authors: K. E. Barbour, J. M. Zmuda, R. Boudreau, E. S. Strotmeyer, M. J. Horwitz, R. W. Evans, A. M. Kanaya, T. B. Harris, J. A. Cauley, The Health ABC Study

Published in: Osteoporosis International | Issue 6/2012

Abstract

Summary

We tested the hypothesis that low leptin and high adiponectin levels are associated with higher rates of bone mineral density (BMD) loss among 3,075 men and women, aged 70–79, from the Health Aging and Body Composition Study. Results suggest that adiponectin, but not leptin, is a risk factor for bone loss in women.

Introduction

Adiponectin and leptin are hormones secreted by adipose cells that may impact BMD. Few studies have evaluated the longitudinal association of leptin and adiponectin levels with rates of BMD change.

Methods

Hip and whole-body areal BMD (aBMD) were measured five times using dual-energy X-ray absorptiometry over 10 years (average follow-up time, 7.95 ± 1.92 years). Trabecular lumbar spine volumetric BMD (vBMD) was measured using quantitative computed topography at baseline and year 6 in the Pittsburgh cohort only. Random slope and intercept models were used to account for within person correlation as a result of repeated measures of hip and whole-body aBMD. Linear regression was used to model changes in spine trabecular vBMD.

Results

Among women, the annualized rate of hip aBMD loss in the highest tertile of adiponectin was −0.67% (95% CI −0.77, −0.58) compared to [−0.43% (95% CI −0.51, −0.35)] in the lowest tertile (p trend = 0.019) after adjusting for age, race, BMI, diabetes, baseline hip aBMD, and weight change. In men, hip aBMD loss was greatest in the high adiponectin group (tertile 3), however this association was not significant (p trend = 0.148). After adjusting for weight change in women, the association between higher leptin and lower hip aBMD loss was attenuated and no longer significant (p trend = 0.134). Leptin and adiponectin levels were not associated with whole-body aBMD or trabecular lumbar spine vBMD loss.

Conclusions

Adiponectin was associated with increased hip aBMD loss in women only, supporting evidence that adiponectin may have an important role in bone health.

Spiegelman BM, Flier JS (2001) Obesity and the regulation of energy balance. Cell 104:531–543PubMedCrossRef

Henry BA, Goding JW, Alexander WS et al (1999) Central administration of leptin to ovariectomized ewes inhibits food intake without affecting the secretion of hormones from the pituitary gland: evidence for a dissociation of effects on appetite and neuroendocrine function. Endocrinology 140:1175–1182PubMedCrossRef

Hinoi E, Gao N, Jung DY et al (2009) An osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Ann N Y Acad Sci 1173(Suppl 1):E20–E30PubMedCrossRef

Handschin AE, Trentz OA, Hemmi S et al (2007) Leptin increases extracellular matrix mineralization of human osteoblasts from heterotopic ossification and normal bone. Ann Plast Surg 59:329–333PubMedCrossRef

Scariano JK, Garry PJ, Montoya GD, Chandani AK, Wilson JM, Baumgartner RN (2003) Serum leptin levels, bone mineral density and osteoblast alkaline phosphatase activity in elderly men and women. Mech Aging Dev 124:281–286PubMedCrossRef

Goldstone AP, Howard JK, Lord GM et al (2002) Leptin prevents the fall in plasma osteocalcin during starvation in male mice. Biochem Biophys Res Commun 295:475–481PubMedCrossRef

Hamrick MW, la-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA (2005) Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20:994–1001PubMedCrossRef

Ducy P, Amling M, Takeda S et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207PubMedCrossRef

Lorentzon M, Landin K, Mellstrom D, Ohlsson C (2006) Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 21:1871–1878PubMedCrossRef

10.

Morberg CM, Tetens I, Black E et al (2003) Leptin and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol Metab 88:5795–5800PubMedCrossRef

11.

Pasco JA, Henry MJ, Kotowicz MA et al (2001) Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86:1884–1887PubMedCrossRef

12.

Ruhl CE, Everhart JE (2002) Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res 17:1896–1903PubMedCrossRef

13.

Blain H, Vuillemin A, Guillemin F et al (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030–1035PubMedCrossRef

14.

Jurimae J, Jurimae T, Leppik A, Kums T (2008) The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab 26:618–623PubMedCrossRef

15.

Jurimae J, Kums T, Jurimae T (2009) Adipocytokine and ghrelin levels in relation to bone mineral density in physically active older women: longitudinal associations. Eur J Endocrinol 160:381–385PubMedCrossRef

16.

Weiss LA, Barrett-Connor E, von MD, Clark P (2006) Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo study. J Bone Miner Res 21:758–764PubMedCrossRef

17.

Chanprasertyothin S, Saetung S, Payattikul P, Rajatanavin R, Ongphiphadhanakul B (2006) Relationship of body composition and circulatory adiponectin to bone mineral density in young premenopausal women. J Med Assoc Thai 89:1579–1583PubMed

18.

Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef

19.

Goldstein BJ, Scalia R (2004) Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563–2568PubMedCrossRef

20.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737PubMedCrossRef

21.

Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef

22.

Yatagai T, Nagasaka S, Taniguchi A et al (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274–1278PubMedCrossRef

23.

Berner HS, Lyngstadaas SP, Spahr A et al (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849PubMedCrossRef

24.

Luo XH, Guo LJ, Xie H et al (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656PubMedCrossRef

25.

Basurto L, Galvan R, Cordova N et al (2009) Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol 160:289–293PubMedCrossRef

26.

Gonnelli S, Caffarelli C, Del SK et al (2008) The relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. Calcif Tissue Int 83:55–60PubMedCrossRef

27.

Jurimae J, Jurimae T (2007) Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int 18:1253–1259PubMedCrossRef

28.

Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517–1523PubMedCrossRef

29.

Michaelsson K, Lind L, Frystyk J et al (2008) Serum adiponectin in elderly men does not correlate with fracture risk. J Clin Endocrinol Metab 93:4041–4047PubMedCrossRef

30.

Araneta MR, von MD, Barrett-Connor E (2009) Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone Miner Res 24:2016–2022PubMedCrossRef

31.

Dennsion EM et al (2004) Plasma leptin concentration and change in bone density among elderly men and women: the Hertfordshire Cohort Study. Calcif Tissue Int 74:401–406

32.

Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P (1994) Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405–411PubMedCrossRef

33.

Ainsworth BE, Haskell WL, Whitt MC et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32:S498–S504PubMedCrossRef

34.

Zoico E, Zamboni M, Adami S et al (2003) Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf) 59:97–103CrossRef

35.

Thomas T, Burguera B, Melton LJ III et al (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114–120PubMedCrossRef

36.

Yamauchi M, Sugimoto T, Yamaguchi T et al (2001) Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 55:341–347CrossRef

37.

Barbour KE, Zmuda JM, Boudreau R et al (2011) Adipokines and the risk of fracture in older adults. J Bone Miner Res 26:1568–1576PubMedCrossRef

38.

Ealey KN, Kaludjerovic J, Archer MC, Ward WE (2008) Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546–1553CrossRef

39.

Johansson C, Black D, Johnell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190–196PubMedCrossRef

Title: The effects of adiponectin and leptin on changes in bone mineral density
Authors: K. E. Barbour
J. M. Zmuda
R. Boudreau
E. S. Strotmeyer
M. J. Horwitz
R. W. Evans
A. M. Kanaya
T. B. Harris
J. A. Cauley
The Health ABC Study
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 6/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1768-x

At a glance: The STEP trials

Springer Medicine

The effects of adiponectin and leptin on changes in bone mineral density

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

Osteoblastogenesis regulation signals in bone remodeling

Forearm bone mineral density changes during postpartum and the effects of breastfeeding, amenorrhea, body mass index and contraceptive use

Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis

Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey